Across TCGA pan-cancer cohorts, TCEAL2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TCEAL2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TCEAL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TCEAL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TCEAL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	1.000	0.330	.038	18	view →
CCRCC	OS	Median	All	1.000	0.734	.010	13	view →
LUAD	OS	Tertile	All	0.889	0.551	.013	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TCEAL2 tumor-vs-normal RNA expression · all TCEAL2 data types